Foresite Capital Fund IV, L.P. 13D and 13G filings for Lyell Immunopharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 2:20 pm Purchase |
2024-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 19,478,893 6.700% |
5,795,035 (+42.35%) |
Filing |
| 2024-10-31 6:00 pm Purchase |
2024-10-25 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 13,683,858 5.300% |
3,683,858 (+36.84%) |
Filing |
| 2023-02-13 5:02 pm Sale |
2022-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 10,000,000 4.000% |
-3,282,181 (-24.71%) |
Filing |
| 2022-02-11 3:10 pm Purchase |
2021-12-31 | 13G | Lyell Immunopharma, Inc. LYEL |
Foresite Capital Fund IV, L.P. | 13,282,181 5.500% |
13,282,181 (New Position) |
Filing |